Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials

Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of coronavirus disease 2019 (COVID‐19). Conventional meta‐analyses cannot fully address the heterogeneity of different designs and outcomes of randomized controlled trials (RCTs) assessing the efficacy of HCQ in o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitjà, Oriol, Reis, Gilmar, Boulware, David R., Spivak, Adam M., Sarwar, Ammar, Johnston, Christine, Webb, Brandon, Hill, Michael D., Smith, Davey, Kremsner, Peter, Curran, Marla, Carter, David, Alexander, Jim, Corbacho, Marc, Lee, Todd C., Hullsiek, Katherine Huppler, McDonald, Emily G., Hess, Rachel, Hughes, Michael, Baeten, Jared M., Schwartz, Ilan, Metz, Luanne, Richer, Lawrence, Chew, Kara W., Daar, Eric, Wohl, David, Dunne, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014689/
https://www.ncbi.nlm.nih.gov/pubmed/36601684
http://dx.doi.org/10.1111/cts.13468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014689/
https://www.ncbi.nlm.nih.gov/pubmed/36601684
http://dx.doi.org/10.1111/cts.13468

Ejemplares similares